Skip to main content

USPTO Reaffirms Rejection of Helicos Patent

Premium

The United States Patent and Trademark Office has reaffirmed its rejection of the last of four patents owned by Helicos BioSciences that are subject to an inter partes reexamination.

In early January, the USPTO issued a so-called action closing prosecution for the patent, US Patent No. 7,767,400, in which it maintained its initial non-final rejection of all of its claims.

Last year, the office had already issued ACPs for the other three patents under reexamination, US Patents No. 7,037,687, No. 7,169,560, and No. 7,645,596 (IS 10/25/2012).

Pacific Biosciences had requested the reexamination of all four patents last year. The USPTO granted the request last spring, rejecting their claims in a non-final office action.

PacBio's request followed after Helicos sued PacBio, Life Technologies, and Illumina in 2010, claiming that their respective technologies infringe on the patents. That action is still ongoing.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.